AlphaStreet Newsdesk powered by AlphaStreet Intelligence
West Pharmaceutical Services, Inc. delivered a strong second quarter, with adjusted-diluted earnings of $2.37 per share, beating the $2.08 consensus estimate by 13.9%. Revenue came in at $872.3M, topping the $840.0M estimate by 3.8% and marking a 13.8% increase from $766.5M in Q2 2025. The pharmaceutical packaging and delivery systems manufacturer reported adjusted net income of $169.4M for the quarter.
The company’s Proprietary Products segment drove performance, generating $722.6M in revenue with year-over-year growth of 16.6%. Total organic growth reached 12.7% for the quarter, reflecting sustained demand for the company’s containment and delivery solutions used by pharmaceutical and biotech customers. West operated 26 manufacturing facilities worldwide at quarter end, supporting its global customer base.
For fiscal year 2026, management set adjusted EPS guidance at $8.85 to $9.05, with revenue guidance ranging from $3.35B to $3.38B. The outlook reflects continued strength in the pharmaceutical packaging sector as drug manufacturers expand production capacity.
Wall Street maintains a positive view on the stock, with analyst consensus at 12 buy ratings, 2 hold ratings, and zero sell recommendations. The company’s performance comes as pharmaceutical manufacturers continue investing in advanced drug delivery systems and injectable treatments.
A detailed analysis of West Pharmaceutical Services, Inc.’s quarter follows shortly on AlphaStreet.
This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.
